Richard C. Chao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard C. Chao has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- James G. Christensen
Mirati Therapeutics, San Diego, California
41 shared publications - Melissa Lynne Johnson
Sarah Cannon Research Institute, Nashville, TN, USA
41 shared publications - Pasi A. Janne
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
41 shared publications - Sai-Hong Ignatius Ou
University of California Irvine School of Medicine, Orange, CA
41 shared publications - Alexander I. Spira
Virginia Cancer Specialists Research Institute, Fairfax, VA
40 shared publications - Cloud P. Paweletz
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
40 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Demographics and Baseline Characteristics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Demographics and Baseline Characteristics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 4: Radiographic response of patients that cleared their plasma (teal) at cycle 4 versus that did not (red).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 4: Radiographic response of patients that cleared their plasma (teal) at cycle 4 versus that did not (red).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results.ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results.ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Demographics and Baseline Characteristics
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Demographics and Baseline Characteristics
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C mutant lung cancer. Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRASG12C-mutant lung cancer patients that participated in cohort A of the KRYSTAL-1 clinical trial. We analyzed the change in ctDNA at 2 specific intervals: between cycles 1 and 2 and at cycle 4. Changes in ctDNA were compared to clinical and radiographic response. Results: We found that, in general, a maximal response in KRAS G12C ctDNA levels could be observed during the initial ~3-week treatment period, well before the first scan at approximately 6 weeks. 35 patients (89.7%) exhibited a decrease in KRAS G12C cfDNA >90% and 33 pts (84.6%) achieved complete clearance by cycle 2. Patients with complete ctDNA clearance at cycle 2 showed an improved objective response rate (ORR) compared to patients with incomplete ctDNA clearance (60.6% vs 33.3%). Furthermore, complete ctDNA clearance at cycle 4 was associated with an improved overall survival (14.7 months vs 5.4 months) and progression free survival (HR 0.3). Conclusion: These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C mutant lung cancer. Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRASG12C-mutant lung cancer patients that participated in cohort A of the KRYSTAL-1 clinical trial. We analyzed the change in ctDNA at 2 specific intervals: between cycles 1 and 2 and at cycle 4. Changes in ctDNA were compared to clinical and radiographic response. Results: We found that, in general, a maximal response in KRAS G12C ctDNA levels could be observed during the initial ~3-week treatment period, well before the first scan at approximately 6 weeks. 35 patients (89.7%) exhibited a decrease in KRAS G12C cfDNA >90% and 33 pts (84.6%) achieved complete clearance by cycle 2. Patients with complete ctDNA clearance at cycle 2 showed an improved objective response rate (ORR) compared to patients with incomplete ctDNA clearance (60.6% vs 33.3%). Furthermore, complete ctDNA clearance at cycle 4 was associated with an improved overall survival (14.7 months vs 5.4 months) and progression free survival (HR 0.3). Conclusion: These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.